Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Coramitug phase 2 trial in ATTR cardiomyopathy
NL-OMON58660Phase 2Completed
- Sponsor
- Novo Nordisk
- Start
- Jul 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of coramitug in amyloidotic transthyretin cardiomyopathy (ATTR-CM) and transthyretin amyloidosis (ATTR) (3 arms), sponsored by Novo Nordisk. Primary endpoints: Change in 6-minute walk test and Change in NT-proBNP. Started Jul 2023; status: completed.
02
Drugs
coramitug
03
Conditions
amyloidotic transthyretin cardiomyopathy (ATTR-CM)transthyretin amyloidosis (ATTR)
Beyond the preview
Go deeper on NL-OMON58660.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58660.